GlassScriptPhysician profile
Seleste Upshaw
NPI 1710542717
$5,868.82
in general payments reported to CMS, 2019-2025
31 companies · $911 in 2025
The $911 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $857 · 2022: $1,575 · 2023: $1,638 · 2024: $888 · 2025: $911.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,436.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,436.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,289.89 | 2021-2024 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $908.86 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $703.92 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $342.08 | 2022-2025 | Mounjaro, Zepbound |
| Abbott Laboratories | $293.71 | 2023-2025 | Freestyle Libre 3 |
| Pfizer INC. | $275.73 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $230.92 | 2021-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $217.52 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Dexcom, INC. | $198.22 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $155.01 | 2021-2024 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $143.22 | 2022-2025 | Xifaxan |
| Amgen INC. | $126.93 | 2022 | |
| Eisai INC. | $121.96 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $121.95 | 2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $121.47 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $120.22 | 2025 | Auvelity |
| Alkermes, INC. | $76.70 | 2023 | Aristada, Lybalvi |
| Xeris Pharmaceuticals, INC. | $73.95 | 2024 | Recorlev |
| Biogen, INC. | $70.94 | 2023 | |
| Genzyme Corporation | $64.96 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $40.88 | 2021-2025 | Austedo Xr, Uzedy |
| Csl Behring | $25.09 | 2024 | Kcentra |
| Mylan Specialty L.P. | $25.01 | 2023 | Yupelri |
| Exact Sciences Corporation | $19.19 | 2025 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $18.00 | 2021 | |
| Astellas Pharma US INC | $16.21 | 2023 | Myrbetriq |
| Indivior INC. | $14.88 | 2023 | Sublocade |
| Idorsia Pharmaceuticals US INC | $13.43 | 2023 | Quviviq |
| Glaxosmithkline, LLC. | $13.39 | 2023 | Shingrix, Arexvy |
| Edwards Lifesciences Corporation | $13.30 | 2022 | |
| Sanofi Pasteur INC. | $11.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seleste Upshaw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.